NICE recommends adalimumab as treatment for plaque psoriasis

National report

- The National Institute for Health and Clinical Excellence (NICE) is recommending adalimumab as a treatment for adults with plaque psoriasis, redOrbit reports.

NICE is recommending the drug for those whom anti-tumor necrosis factor treatment is being considered and when the following criteria are both met: The disease is severe as defined by a total Psoriasis Area Severity Index of 10 or more and a Dermatology Life Quality Index of more than 10, and when the psoriasis has not responded to standard systemic therapies or if the person is intolerant of or has a contraindication to these treatments.